|
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
JH013注射液在健康受试者中的安全性、耐受性、药代动力学、药效学的I期临床试验
[Translation] Phase I clinical trial of the safety, tolerability, pharmacokinetics and pharmacodynamics of JH013 injection in healthy subjects
主要目的:评价JH013在健康受试者中单次给药后的安全性和耐受性;
次要目的:评价JH013在健康受试者中单次给药后的药代动力学特征、药效学特征以及JH013的免疫原性
[Translation] Primary objective: To evaluate the safety and tolerability of JH013 after a single dose in healthy subjects;
Secondary objective: To evaluate the pharmacokinetic and pharmacodynamic characteristics of JH013 after a single dose in healthy subjects and the immunogenicity of JH013
100 Clinical Results associated with Ambotek Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Ambotek Pharmaceutical Co., Ltd.
100 Deals associated with Ambotek Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Ambotek Pharmaceutical Co., Ltd.